{
    "clinical_study": {
        "@rank": "99030", 
        "arm_group": {
            "arm_group_label": "Treatment (autologous T cells and aldesleukin)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo radiation therapy or recombinant interferon beta intralesional injection within day -3 to day -1.\nPatients receive MCPyV TAg-specific polyclonal autologous CD8-positive T cell infusion IV on day 1 and aldesleukin SC every 12 hours on days 1-14. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.\nPatients with continued presence of detectable metastatic disease 8 weeks after the first infusion may repeat the treatment regimen including radiation therapy or recombinant interferon beta injection."
        }, 
        "brief_summary": {
            "textblock": "This phase I/II trial studies the side effects and best way to give laboratory treated\n      autologous T cells together with aldesleukin and to see how well it works in treating\n      patients with metastatic merkel cell carcinoma. Biological therapies, such as cellular\n      adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor\n      cells from growing. Aldesleukin may stimulate the white blood cells to kill tumor cells.\n      Giving cellular adoptive immunotherapy with aldesleukin may be a more effective treatment\n      for metastatic merkel cell carcinoma."
        }, 
        "brief_title": "Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma", 
        "condition": [
            "Recurrent Neuroendocrine Carcinoma of the Skin", 
            "Stage IV Neuroendocrine Carcinoma of the Skin"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Merkel Cell", 
                "Carcinoma, Neuroendocrine", 
                "Skin Neoplasms", 
                "Carcinoma, Basal Cell", 
                "Carcinoma, Basosquamous", 
                "Carcinoma, Squamous Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Determine the safety and potential toxicities associated with treating patients with\n      metastatic merkel cell carcinoma (MCC) by combined myosin heavy chain (MHC) up-regulation\n      therapy and adoptive transfer of merkel cell polyomavirus (MCPyV) T-antigen (TAg)-specific\n      polyclonal autologous cluster of differentiation (CD)8+ T cells.\n\n      II. Determine the antitumor efficacy associated with treating patients with metastatic MCC\n      by combined MHC up-regulation therapy and adoptive transfer of MCPyV TAg-specific polyclonal\n      autologous CD8+ T cells.\n\n      SECONDARY OBJECTIVES:\n\n      I. Determine the in vivo persistence and where evaluable, migration to tumor sites of\n      adoptively transferred polyclonal CD8+ T cells targeting the MCPyV TAg.\n\n      II. Determine the in vivo functional capacity of adoptively transferred polyclonal CD8+ T\n      cells targeting the MCPyV TAg.\n\n      OUTLINE:\n\n      Patients undergo radiation therapy or recombinant interferon beta intralesional injection\n      within day -3 to day -1.\n\n      Patients receive MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine\n      intravenously (IV) on day 1 and aldesleukin subcutaneously (SC) every 12 hours on days 1-14.\n      Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or\n      unacceptable toxicity.\n\n      Patients with continued presence of detectable metastatic disease 8 weeks after the first\n      infusion may repeat the treatment regimen including radiation therapy or recombinant\n      interferon beta injection.\n\n      After completion of study treatment, patients are followed up every 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histopathological documentation of MCC concurrent with the diagnosis of metastatic\n             disease\n\n          -  Evidence of MCPyV TAg tumor expression\n\n          -  Available peptide-MHC pair that can be folded into a tetramer for which MCPyV\n             TAg-specific cells can be generated and reactivity to cell lines expressing MCPyV TAg\n             with the corresponding human leukocyte antigen (HLA)\n\n          -  Bi-dimensionally measurable disease by palpation, clinical exam, or radiographic\n             imaging (x-ray, computed tomography [CT] scan, positron emission tomography [PET]\n             scan, magnetic resonance imaging [MRI], or ultrasound)\n\n          -  At least 3 weeks must have passed since any of the following: systemic\n             corticosteroids, immunotherapy (for example, interleukins, MCC vaccines, intravenous\n             immunoglobulin, expanded polyclonal tumor infiltrating lymphocyte [TIL] or\n             lymphokine-activated killer [LAK] therapy), pentoxifylline, other small molecule or\n             chemotherapy cancer treatment, other investigational agents or other agents that\n             target merkel cell carcinoma\n\n        Exclusion Criteria:\n\n          -  Unable to generate antigen-specific MCPyV TAg-specific CD8+ T cells for infusions\n\n          -  Active infections or oral temperature > 38.2 Celsius (C) fewer than 72 hours prior to\n             receiving study treatment or systemic infection requiring chronic maintenance or\n             suppressive therapy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status > 2\n\n          -  White blood cell (WBC) < 2000/mcl\n\n          -  Hemoglobin (Hb) < 8 g/dL\n\n          -  Absolute neutrophil count (ANC) < 1000/mcl\n\n          -  Platelets < 50,000/mcl\n\n          -  New York Heart Association functional class III-IV heart failure, symptomatic\n             pericardial effusion, stable or unstable angina, symptoms of coronary artery disease,\n             congestive heart failure, clinically significant hypotension, or an ejection fraction\n             of =< 30 % (echocardiogram or multi gated acquisition scan [MUGA])\n\n          -  Clinically significant pulmonary dysfunction, as determined by medical history and\n             physical exam; patients so identified will undergo pulmonary functions testing and\n             those with forced expiratory volume in one second (FEV1) < 2.0 L or diffusing\n             capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin [Hgb]) <\n             50% will be excluded\n\n          -  Creatinine clearance < 30 ml/min which cannot be attributed to MCC metastasis\n\n          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5 x upper limit of\n             normal (ULN)\n\n          -  Bilirubin > 3 x ULN which cannot be attributed to MCC metastasis\n\n          -  Active autoimmune disease (e.g. systemic lupus erythematosus, vasculitis,\n             infiltrating lung disease, inflammatory bowel disease) whose possible progression\n             during treatment would be considered unacceptable by the investigators\n\n          -  Symptomatic and untreated central nervous system (CNS) metastasis; however, patients\n             with 1-2 asymptomatic, less than 1 cm brain/CNS metastases without significant edema\n             may be considered for treatment; if sub-centimeter CNS lesions are noted at study\n             entry, then a repeat imaging will be performed if more than 4 weeks have elapsed from\n             the last scan\n\n          -  Any condition or organ toxicity that is deemed by the principal investigator (PI) or\n             the attending physician to place the patient at unacceptable risk for treatment on\n             the protocol\n\n          -  Pregnant women, nursing mothers, men or women of reproductive ability who are\n             unwilling to use effective contraception or abstinence; women of childbearing\n             potential must have a negative pregnancy test within two weeks prior to entry\n\n          -  Clinically significant and ongoing immune suppression including, but not limited to,\n             systemic immunosuppressive agents such as cyclosporine or corticosteroids, chronic\n             lymphocytic leukemia (CLL), uncontrolled human immunodeficiency virus (HIV)\n             infection, or solid organ transplantation\n\n          -  Patients may not be on any other treatments for their cancer aside from those\n             included in the protocol; patients may not undergo another form of treatment\n             concurrently with this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01758458", 
            "org_study_id": "2586.00", 
            "secondary_id": [
                "NCI-2012-02779", 
                "2586.00", 
                "P30CA015704"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (autologous T cells and aldesleukin)", 
                "description": "Undergo radiation therapy", 
                "intervention_name": "radiation therapy", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "irradiation", 
                    "radiotherapy", 
                    "therapy, radiation"
                ]
            }, 
            {
                "arm_group_label": "Treatment (autologous T cells and aldesleukin)", 
                "description": "Given intralesionally", 
                "intervention_name": "recombinant interferon beta", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Betantrone", 
                    "Betaseron", 
                    "IFN-B", 
                    "Naferon", 
                    "Rebif"
                ]
            }, 
            {
                "arm_group_label": "Treatment (autologous T cells and aldesleukin)", 
                "description": "Given IV", 
                "intervention_name": "MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine", 
                "intervention_type": "Biological", 
                "other_name": "MCPyV TAg-specific polyclonal autologous CD8-positive T cells"
            }, 
            {
                "arm_group_label": "Treatment (autologous T cells and aldesleukin)", 
                "description": "Given SC", 
                "intervention_name": "aldesleukin", 
                "intervention_type": "Biological", 
                "other_name": [
                    "IL-2", 
                    "Proleukin", 
                    "recombinant human interleukin-2", 
                    "recombinant interleukin-2"
                ]
            }, 
            {
                "arm_group_label": "Treatment (autologous T cells and aldesleukin)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-beta", 
                "Interferons", 
                "Aldesleukin", 
                "Interleukin-2"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "contact": {
                "last_name": "Aude Chapuis", 
                "phone": "206-667-4369"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
            }, 
            "investigator": {
                "last_name": "Aude Chapuis", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", 
            "last_name": "Aude Chapuis", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The treatment will be considered to have an acceptable safety profile if the observed toxicity rate is consistent with a true rate that does not exceed 30%.", 
                "measure": "Evidence and nature of toxicity related to the study treatment assessed using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "description": "Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.", 
                "measure": "Evidence of response based on \"median time to new metastasis\"", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01758458"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Persistence of transferred T cells in blood and in tumor", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "measure": "Functional capacity of transferred T cells", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "measure": "Disease response by RECIST criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "measure": "MCC-specific survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }
        ], 
        "source": "Fred Hutchinson Cancer Research Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}